The global hepatitis testing market is projected to reach USD 3.6 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 4.7% during the forecast period. The growth of the global hepatitis testing market is being driven by factors such as the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on hepatitis. High cost of nucleic acid tests, lack of mandates for nucleic acid tests in developing countries and unfavorable reimbursement scenarios are expected to restrain hepatitis market growth. Emerging markets, rising technological advancements in molecular diagnostics, and growth in the biotechnology and biopharmaceutical industries are expected to offer strong growth opportunities for players in the market. In contrast, changing regulatory landscape, opertationsla barriers and shortage of skilled professionals may challenge market growth to a certain extent. The hepatitis testing market is segmented based on disease type, technology, end user, and region.
The global hepatitis testing market is consolidated. The prominent players operating in this market include include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), QIAGEN (Netherlands), bioMérieux SA (France), DiaSorin S.P.A. (Italy), Ortho Clinical Diagnostics (US), MedMira Inc. (Canada), Fujirebio US, Inc. (Japan), Grifols, S.A. (Spain), Orasure Technologies (US), GenMark Diagnostics Inc. (US), Vela Diagnostics (Singapore), and Epitope Diagnostics (US).
To know about the assumptions considered for the study download the pdf brochure
F. Hoffmann-La Roche Ltd. (Switzerland) is the leading player in the hepatitis testing market in 2020. The company’s large share can be attributed to its broad range of hepatitis testing products. The company’s leading position is attributed to its wide product portfolio, including clinical chemistry and immunochemistry solutions, molecular diagnostic products, tissue diagnostic instruments, reagents, and kits.
Abbott Laboratories (US) accounted for the high share of the hepatitis testing market in 2020. Abbott has a strong presence in the US and seeks to further enhance its geographical presence by strengthening its business operations in emerging high-growth markets. The company has a strong product portfolio, and its FDA- and CE-approved products have helped it to maintain and enhance its presence in the hepatitis testing market.
Siemens Healthineers (Germany) held the third position in the hepatitis testing market in 2020. The company’s large share in the hepatitis testing market is attributed to its strong geographical presence across the globe and broad portfolio of immunoassays, clinical chemistry, hemostasis, and infectious disease diagnostic products. Over the years, the company has strengthened its presence in the global hepatitis testing market by launching innovative solutions and expanding its presence in high-growth markets.
Hepatitis Testing/Diagnosis Market by Disease Type (Hepatitis B, Hepatitis C, Other Hepatitis), Technology (ELISA, RDT, PCR, INAAT), End User (Hospitals, Diagnostic Laboratories, Blood Banks), and Region - Global Forecast to 2026
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE